Amgen and Takeda - Billion-dollar deals

Who: Amgen
With: Takeda
What: $1 billion licensing deal

Scoop: 2007 was a rough year for Amgen. Safety problems plagued the company's bestselling anemia drugs Aranesp and Epogen, causing sales of the drugs to plummet. Amgen restructured and cut jobs in an effort to cut expenses in the wake of falling profits. Amgen also said it had more drug candidates in its pipeline than it could develop, and Takeda was willing to take the targets off Amgen's hands. Takeda gained 13 experimental therapies in a deal that may be worth more than $1 billion. The move marks Takeda's entry into the biologics market.

Amgen and Takeda - Billion-dollar deals

Suggested Articles

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.